5 results about "Abnormal liver function" patented technology

The application discloses a kind of liver disease treatment gene target and drug.The liver function and liver tissue of Ndufa7 gene knockout mouse are detected and analyzed by the present application, and it is found that knockout Ndufa7 gene will cause abnormal liver function of mouse, liver tissue is damaged, and it is found that the expression of Ndufa7 gene can be induced by real-time quantitative fluorescence PCR to induce the occurrence of non-alcoholic fatty liver disease, and Ndufa7 gene can be used as liver disease treatment gene target to develop liver disease treatment drug.In addition, the present application finds that the survival rate of cell under the stimulation of oleic acid can be improved by overexpressing Ndufa7 gene in cell, and oleic acid is a common reagent for inducing non-alcoholic fatty liver cell model, i.e.overexpression Ndufa7 gene can prevent or improve liver disease, and can be used as liver disease treatment drug.The present application fully proves that Ndufa7 is involved in the occurrence of liver disease, and is beneficial to the development of drug for preventing, improving or treating liver disease.

The invention discloses an establishment method and application of a type-1 autoimmune hepatitis mouse model, and relates to the technical field of biology, and the technical key points are as follows: an adenovirus is combined with an overexpression Sepsecs plasmid to realize continuous expression of autoantigen in the liver, a chronic liver inflammation model conforming to type-1 AIH characteristics is successfully induced in a mouse body for the first time, and the mouse model has a good application prospect. The model shows clinical pathological characteristics of continuous infiltration of inflammatory cells, abnormal liver function, autoantibody generation, hepatic tissue fibrosis and the like, and has good stability and repeatability. At present, no type 1 AIH mouse model constructed by using the Sepsecs antigen is publically reported at home and abroad, and the technical blank in the field of type 1 AIH chronic animal models is filled. The model can be used for AIH pathogenesis research, autoantigen screening, novel diagnostic marker discovery, immune intervention means evaluation and clinical verification before new medicine, has wide scientific research and industrial application prospects, and provides an ideal experimental animal model platform.

The present application relates to the field of biological medicine and functional food, and discloses a kind of nutrition composition based on marine shrimp peptide for anti-obesity and improving metabolic syndrome;Including: Chinese tube whip shrimp peptide active component and pharmaceutically acceptable adjuvant, the Chinese tube whip shrimp meat protein is used as raw material, and the Chinese tube whip shrimp meat protein is prepared by alkaline protease enzymolysis, and the Chinese tube whip shrimp meat protein contains peptide segment with molecular weight less than 1 kDa, and APPPPP, HPPPP and MPLPP can be detected.The pharmaceutical composition can reduce the weight and fat tissue weight under the state of obesity, improve dyslipidemia, abnormal liver function and liver steatosis, reduce oxidative stress level, improve intestinal mucosal barrier damage and intestinal permeability increase, and regulate intestinal flora structure change.The active component in the present application is clear in origin, and the preparation process is clear, has the synergistic effect from lipid metabolism regulation, liver protection to intestinal barrier improvement, and can be used for preparing medicine for preventing or treating obesity and improving metabolic syndrome.

The present application relates to the application of mitochondrial transplantation preparation in the preparation of a drug for treating non-alcoholic fatty liver disease, wherein the mitochondrial transplantation preparation comprises active mitochondria isolated from healthy donor cells, and has normal membrane potential and mitochondrial respiratory function. In vivo experiments on a non-alcoholic fatty liver mouse model prove that tail vein injection of the mitochondrial transplantation preparation of the present application can effectively reduce the weight of the mouse, improve the fatty liver condition of the mouse, reduce the accumulation of fat in the liver tissue, and at the same time restore the abnormal liver function of the non-alcoholic fatty liver mouse.

The invention belongs to the technical field of food fermentation, and discloses an anti-aging, anti-oxidation and blood fat-reducing enzyme liquid and a preparation method thereof. The enzyme liquid is prepared by taking 2-5 parts of hawthorn, 2-5 parts of apple, 1-3 parts of lemon, 0.8-1.5 parts of ginkgo and 1.5-2.5 parts of broken rock sugar as main raw materials, supplementing mountain spring water and honey, and performing raw material pretreatment, primary constant-temperature fermentation and secondary constant-temperature fermentation. The ginkgo seeds are boiled to remove toxins, the primary fermentation is carried out at 28-35 DEG C for 60-90 days, and the secondary fermentation is carried out at 25-32 DEG C for 25-35 days. The prepared enzyme liquid is yellowish, transparent and bright and fragrant in smell, has the remarkable effects of resisting oxidation and aging and assisting in reducing blood fat, can improve intestinal flora and whiten skin, and is suitable for auxiliary conditioning of hyperlipidemia, nephritis and abnormal liver function. The invention has the advantages of scientific formula, controllable process, high safety and good stability, and is suitable for industrial production and market promotion.